Marilia Martins

Marilia Martins

Auto-generated profile, based on publicly available information

Marilia Martins

Universidade Estadual de Campinas, Área de Cardiologia, Brazil

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2024 in Brazilian Journal of Nephrology
Verified
Journal Article
Open access
PDF file
JBJoaquim Barreto
Joaquim Barreto
MMMarilia Martins
Marilia Martins
CBCynthia M. Borges
Cynthia M. Borges
SVSofia Helena Vitte
Sofia Helena Vitte
WNWilson Nadruz
Wilson Nadruz
ASAndrei C Sposito
Andrei C Sposito
The accumulation of advanced glycation end-products (AGEs) elicits morphofunctional kidney impairment. AGEs levels can be noninvasively estimated by skin autofluorescence (SAF). We explored whether high SAF predicts kidney outcomes in type 2 diabetes (T2D) individuals. The study was conducted as a predefined analysis of the Brazilian Diabetes Study, a prospective single-center cohort of T2D adults. Data from 155 individuals followed for up to 1716 days were considered. The incidence of major adverse kidney events (MAKE) was 9.6%. Individuals with above-median SAF had a higher incidence of MAKEs (4.6% vs. 21%; p = 0.002), with an HR of 3.39 [95% CI: 1.06–10.85; p = 0.040] after adjustment by age and gender. The mean adjusted eGFR change was 1.08 units (SE: 1.15; 95%CI: –1.20, 3.37) in the low SAF and –5.19 units [SE: 1.93; 95%CI: –9.10, –1.29] in the high SAF groups (between-subject difference: F: 5.62, p = 0.019). The high-SAF group had a greater prevalence of rapid decliners than the low-SAF group (36.7% vs. 15.8%; p = 0.028). In conclusion, high SAF was related to increased incidence of MAKEs and faster decline in eGFR among T2D subjects. This should be considered by healthcare providers when identifying individuals more prone to diabetes-related kidney complications.

1 December 2024 in Brazilian Journal of Nephrology
Verified
Journal Article
Open access
PDF file
JBJoaquim Barreto
Joaquim Barreto
MMMarilia Martins
Marilia Martins
CBCynthia M. Borges
Cynthia M. Borges
SVSofia Helena Vitte
Sofia Helena Vitte
WNWilson Nadruz
Wilson Nadruz
ASAndrei C Sposito
Andrei C Sposito
O acúmulo de produtos finais de glicação avançada (AGEs, do inglês advanced glycation end-products) provoca comprometimento morfofuncional dos rins. Os níveis de AGEs podem ser estimados de forma não invasiva por autofluorescência da pele (sAF). Exploramos se a sAF elevada prediz desfechos renais em indivíduos com diabetes tipo 2 (DT2). O estudo foi realizado como uma análise predefinida do Estudo Brasileiro sobre Diabetes, uma coorte prospectiva de centro único de adultos com DT2. Foram considerados os dados de 155 indivíduos acompanhados por até 1.716 dias. A incidência de eventos renais adversos maiores (MAKE, por sua sigla em inglês) foi de 9,6%. Indivíduos com sAF acima da mediana apresentaram maior incidência de MAKEs (4,6% vs. 21%; p = 0,002), com HR de 3,39 [IC 95%: 1,06–10,85; p = 0,040] após ajuste por idade e sexo. A alteração média da TFGe ajustada foi de 1,08 unidades (EP: 1,15; IC95%: –1,20, 3,37) no grupo de baixa sAF e de –5,19 unidades [EP: 1,93; IC95%: –9,10, –1,29] no grupo de elevada sAF (diferença entre sujeitos: F: 5,62; p = 0,019). O grupo sAF elevada apresentou maior prevalência de declínio rápido em comparação ao grupo sAF baixa (36,7% vs. 15,8%; p = 0,028). Em conclusão, a sAF elevada foi relacionada ao aumento da incidência de MAKEs e ao declínio mais rápido da TFGe entre indivíduos com DT2. Tal fato deve ser considerado pelos profissionais de saúde ao identificar indivíduos mais propensos a complicações renais relacionadas ao diabetes.

14 August 2026 in Calcified Tissue International
Verified
Journal Article
Open access
PDF file
LPLauter Eston Pelepenko
Lauter Eston Pelepenko
JBJoaquim Barreto
Joaquim Barreto
MMMarília P. Martins
Marília P. Martins
PCPedro B. Chiteculo
Pedro B. Chiteculo
JCJessica M. Camargo
Jessica M. Camargo
RORodrigo Bueno de Oliveira
Rodrigo Bueno de Oliveira
The effects of gliflozins on bones of CKD patients on dialysis are unknown. Recently, SGLT2 expression in bone tissue of patients with CKD has been reported. We hypothesized that dapagliflozin may act in bone cells and modulate the Klotho-FGF23 axis. This study analyzed the effects of dapagliflozin on serum bone biomarkers and related outcomes. In this predefined post-hoc analysis of a previous RCT, patients on dialysis received (1:1) dapagliflozin 10 mg daily or standard care for 24 weeks. The primary endpoint was the change from baseline in serum Klotho and FGF23 levels, compared by ranked analysis of covariance, adjusted by baseline. Exploratory analyses evaluated calcium, phosphate, PTH, bone-ALP, TRAP-5b, DKK1, sclerostin, and bone proteins. Bone fractures, osteopenia, and osteoporosis were outcomes of interest. Seventy-nine patients were included in this analysis (Control N=40 and Dapagliflozin N=39). At baseline, no significant differences in biomarkers were observed. The prevalence of osteopenia and osteoporosis was 73% and 43% ( p = 0.60 and p = 1.00), respectively. After 24 weeks, the between-group analysis of the change from baseline (delta), adjusted by baseline, revealed a significant difference in serum Klotho [19.1 (− 38.9–86.3) pg/mL, Control group; − 29.1 (− 94.1–43.9) pg/mL, Dapagliflozin group (F:4.946, p = 0.03)], but not on FGF23 levels, nor other biomarkers. The follow-up prevalences of osteopenia and osteoporosis were 70% and 48% ( p = 0.27 and p = 0.61, respectively). No bone fractures were observed. Dapagliflozin use over 24 weeks in patients on dialysis was independently associated with lowered serum Klotho levels, without effects in other bone biomarkers or related outcomes.

1 January 2026 in Arquivos Brasileiros de Cardiologia
Verified
Journal Article
Open access
EEEurico Joaquim Lutucuta Ernesto
Eurico Joaquim Lutucuta Ernesto
ANAna Claudia Cavalcante Nogueira
Ana Claudia Cavalcante Nogueira
LSLuis Gustavo Sedenho-Prado
Luis Gustavo Sedenho-Prado
LYLouise Buonalumi Tacito Yugar
Louise Buonalumi Tacito Yugar
MMMarília Paiva Martins
Marília Paiva Martins
ASAndrei C Sposito
Andrei C Sposito
Resumo Fundamento Os bloqueadores dos receptores da angiotensina II (BRAs) antagonizam o receptor AT1 e são anti-hipertensivos eficazes. Diferenças modestas na eficácia da redução da pressão arterial têm sido relatadas, refletindo variações na farmacocinética, na ligação ao receptor, na duração da ação e em potenciais efeitos pleiotrópicos. Entretanto, os dados sobre seus efeitos comparativos nos desfechos cardiovasculares em pacientes são escassos. Objetivo Avaliar os efeitos dos BRAs sobre eventos cardiovasculares adversos maiores (MACE), hospitalização por insuficiência cardíaca (HHF) e mortalidade por todas as causas em ensaios randomizados não delineados primariamente para avaliar insuficiência cardíaca (IC). Métodos As bases de dados MEDLINE/PubMed, Cochrane Central Register of Controlled Trials e ClinicalTrials.gov foram pesquisadas até maio de 2025. Foram incluídos ensaios clínicos randomizados publicados que relataram eventos cardiovasculares adversos maiores (MACE), HHF ou morte por todas as causas, envolvendo BRAs, com pelo menos 100 indivíduos por braço e acompanhamento ≥12 meses. Estudos focados principalmente em pacientes com IC preexistente foram excluídos. Taxas de incidência de HHF, MACE e morte por todas as causas. Foi realizada uma metanálise em rede de efeitos aleatórios, incluindo 27 ensaios clínicos randomizados e 702.584 pacientes-ano. Resultados O candesartana reduziu MACE em comparação ao placebo (OR 0,79; IC 95%, 0,63–0,97; SUCRA=0,85), apresentando a melhor classificação entre os BRAs, enquanto a telmisartana demonstrou uma redução menor, porém significativa (OR 0,90; IC 95%, 0,80–0,99; SUCRA=0,61). A análise baseou-se em dados em nível de estudo; as redes de tratamentos incluídas eram moderadamente esparsas, com comparações predominantemente indiretas entre os BRAs. Conclusão Esta metanálise em rede, realizada em pacientes sem IC basal, indica que a candesartana e a telmisartana reduzem MACE, sugerindo diferenças clinicamente relevantes entre os BRAs. Considerando a natureza predominantemente indireta de várias comparações, esses achados devem ser interpretados com cautela.

1 January 2026 in Arquivos Brasileiros de Cardiologia
Verified
Journal Article
Open access
EEEurico Joaquim Lutucuta Ernesto
Eurico Joaquim Lutucuta Ernesto
ANAna Claudia Cavalcante Nogueira
Ana Claudia Cavalcante Nogueira
LSLuis Gustavo Sedenho-Prado
Luis Gustavo Sedenho-Prado
LYLouise Buonalumi Tacito Yugar
Louise Buonalumi Tacito Yugar
MMMarília Paiva Martins
Marília Paiva Martins
ASAndrei C Sposito
Andrei C Sposito
Background Angiotensin II receptor blockers (ARBs) antagonize the AT1 receptor and are effective antihypertensives. Modest differences in blood pressure-lowering efficacy have been reported, reflecting variations in pharmacokinetics, receptor binding, duration of action, and potential pleiotropic effects. However, data on their comparative effects on cardiovascular outcomes in patients are scarce. Objective To assess the effects of ARBs on MACE, hospitalization for heart failure (HHF), and all-cause mortality in randomized trials not primarily designed to evaluate heart failure (HF). Methods MEDLINE/PubMed, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov databases were searched until May 2025. Published RCTs reporting major adverse cardiovascular events (MACE), HHF or all-cause death, involving ARBs, with at least 100 individuals per arm and ≥12 months of follow-up, were included. Studies focusing primarily on patients with existing HF were excluded. Incidence rates of HHF, MACE, and all-cause death. A random-effects network meta-analysis including 27 RCTs and 702,584 patient-years was performed. Results Candesartan reduced MACE versus placebo (OR 0.79; 95% CI, 0.63–0.97; SUCRA=0.85), ranking highest among ARBs, while telmisartan showed a smaller but significant reduction (OR 0.90; 95% CI, 0.80–0.99; SUCRA=0.61). The analysis relied on study-level data; included moderately sparse treatment networks with predominantly indirect comparisons between ARBs. Conclusion This network meta-analysis in patients without baseline HF indicates that candesartan and telmisartan reduce MACE, suggesting clinically meaningful differences among ARBs. Given the predominantly indirect nature of several comparisons, these findings should be interpreted cautiously.